Molecular subtyping of small cell lung cancer.

Semin Cancer Biol

Department of Thoracic Surgery, First Affiliated Hospital, China Medical University, Shenyang, China. Electronic address:

Published: November 2022

AI Article Synopsis

  • Small cell lung cancer (SCLC) is a serious type of lung cancer with a low 5-year survival rate below 7%, making it a significant public health concern.
  • Recent advances in gene sequencing have improved our understanding of gene mutations and tumor evolution in SCLC, leading to better molecular subtyping which aids in prognosis and treatment planning.
  • This review discusses the progress in mutation-based subtyping and explores current molecular targeting and immunotherapy strategies to enhance individualized treatment for SCLC patients.

Article Abstract

Small cell lung cancer (SCLC), originating from lung neuroendocrine stem cells, is a common pulmonary malignant tumor. SCLC, with poor prognoses, accounts for approximately 13-15% of all lung cancer cases. Due to the slow progress of clinical treatment, the 5-year survival rate of SCLC has remained below 7% for many years. In recent years, with the development and popularity of gene sequencing technologies, we were able to better grasp patterns of gene mutations and tumor evolution in SCLC. Thus, appropriate molecular subtyping strategies have been established to help predict patients' prognoses and develop the treatment regimen for SCLC more accurately. In this narrative review, we aim to summarize the evolution of mutation-based molecular subtyping of SCLC, as well as the trends in molecular targeting and immunotherapeutic for SCLC. Based on the latest sequencing data for SCLC, thereafter, we discuss therapeutic opinions of SCLC from basic to clinic. This review may provide a basis for guiding the development of subsequent individualized precision-targeted therapy for SCLC patients to improve their clinical prognoses.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2022.05.010DOI Listing

Publication Analysis

Top Keywords

molecular subtyping
12
lung cancer
12
sclc
10
small cell
8
cell lung
8
molecular
4
subtyping small
4
lung
4
cancer small
4
cancer sclc
4

Similar Publications

The cell of origin (COO) classification is an expression-based tumor algorithm identifying molecular subtypes of diffuse large B-cell lymphoma (DLBCL) with distinct prognostic characteristics. Traditional immunohistochemical methods for classifying COO subtypes have poor concordance and limited prognostic value in frontline DLBCL. In contrast, RNA-based metrics like the NanoString Lymphoma Subtyping Test (LST) define more robust subtypes with validated prognostic associations.

View Article and Find Full Text PDF

Transcriptional determinants of goal-directed learning and representational drift in the parahippocampal cortex.

Cell Rep

January 2025

Department of Biology, Boston University, Boston, MA 02215, USA; Center for Neurophotonics, Boston University, Boston, MA 02215, USA; Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA; Center for Systems Neuroscience, Boston University, Boston MA 02215, USA. Electronic address:

Task learning involves learning associations between stimuli and outcomes and storing these relationships in memory. While this information can be reliably decoded from population activity, individual neurons encoding this representation can drift over time. The circuit or molecular mechanisms underlying this drift and its role in learning are unclear.

View Article and Find Full Text PDF

Inflammatory bowel disease (IBD) with the two predominant endophenotypes-Crohn's disease (CD) and ulcerative colitis (UC)-represents a group of chronic gastrointestinal inflammatory conditions. Since most genetic associations with IBD are often limited to independent subtypes, we reported a genome-wide association study (GWAS) cross-trait analysis combined with CD and UC to enhance statistical power. Initially, we detected 256 association signals at 54 genomic susceptibility loci and further characterized the functionality of variants within these regions.

View Article and Find Full Text PDF

Radioactive prostate-specific membrane antigen (PSMA)-targeting agents are clinically useful for the diagnosis and treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Neuroendocrine-differentiated prostate cancer (NEPC), a highly aggressive subtype that is strongly associated with a poor clinical prognosis, may present with reduced PSMA expression and evade detection with PSMA-targeted agents. Several studies have shown elevated uptake of somatostatin receptor 2 (SSTR2) ligands in PSMA-negative NEPC.

View Article and Find Full Text PDF

Background: Metastatic retinoblastoma remains a significant challenge in pediatric oncology, with stark disparities in survival outcomes between high-income countries (HICs) and low-income countries (LICs). Delayed diagnosis and treatment, driven by socioeconomic factors and limitations in healthcare systems, contribute to poorer outcomes in LICs. Histopathological characteristics, including high-risk pathology factors (HRPFs) and the extent of ocular tumor invasion, are critical for predicting metastatic risk and guiding treatment strategies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!